Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 14Recruiting 5Active not recruiting 5Unknown 4Not yet recruiting 2Withdrawn 1Terminated 1

Sponsor Class

NIH 3OTHER 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Gynecologic 1

Conditions

Breast Neoplasms 849Carcinoma, Non-Small-Cell Lung 551Neoplasms 509Prostatic Neoplasms 501Lung Neoplasms 313Colorectal Neoplasms 307Multiple Myeloma 289Neoplasm Metastasis 251Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 209Pancreatic Neoplasms 206Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 164Stomach Neoplasms 162Recurrence 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 151Glioblastoma 147Uterine Cervical Neoplasms 144Head and Neck Neoplasms 141Lymphoma, Non-Hodgkin 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 114Lymphoma, Follicular 112

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3Nivolumab 3Biopsy 2dehydroftorafur 1X-Rays 1Watchful Waiting 1Taxes 1Sigmoidoscopy 1Radiotherapy, Intensity-Modulated 1Proctoscopy 1Phantoms, Imaging 1Paclitaxel 1Observation 1Mitozytrex 1Mitomycin 1Ipilimumab 1Fluorouracil 1Fluorodeoxyglucose F18 1Colonoscopy 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Anal Canal Carcinoma × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04444921 2026-05-29

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

National Cancer Institute (NCI)

Phase 3 Active not recruiting
205 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT02314169 2026-05-28

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
143 enrolled 16 charts
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04166318 2026-05-05

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
252 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT03403465 2026-02-27

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

Duke University

Phase 2 Active not recruiting
90 enrolled
GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms, Esophageal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡